P2, N=8, Active, not recruiting, Mayo Clinic | Trial completion date: Mar 2026 --> Jul 2026 | Trial primary completion date: Mar 2026 --> Jul 2026

In this phase II single-arm study, olaparib plus abiraterone and ADT showed preliminary activity and a manageable safety profile in patients with HRR-mutated mHSPC, but these findings need to be confirmed in larger phase III studies.

This study integrated established diagnostic standards, laryngostroboscopy for clinical assessment, and histopathology as the gold standard for grading, while the analysis of SOX2 gene expression showed a promising predictive molecular marker for tumorigenesis.

Paclitaxel (PTX), a broad-spectrum anti-tumor drug, is extensively employed as a first-line chemotherapy for solid tumors, including lung and breast cancers. Compared with PTX-treated mice, S-ketamine administration resulted in significant improvements across behavioral, molecular, and electrophysiological dimensions: significantly increased mechanical withdrawal thresholds indicated alleviated neuropathic pain; Increased central area distance/total distance ratio in the OFT and prolonged open arm time in the EPM demonstrated reduced anxiety-like behaviors; concomitant decreases in mGluR5 expression and pyramidal neuron firing rates were observed alongside enhanced theta-gamma phase-amplitude coupling, and upregulation of BDNF and TrkB expression in the PrL was detected. S-ketamine mitigates PTX-induced mechanical allodynia and anxiety-like behaviors, an effect that is closely associated with the downregulation of mGluR5 and the concurrent modulation of the BDNF/TrkB signaling pathway in the PrL of the mPFC.

To rationalize these effects and explore its therapeutic potential, an integrated in silico approach comprising molecular docking, ADMET prediction, molecular dynamics (MD) simulations, MM/PBSA binding free energy calculations, and density functional theory (DFT) analyses was performed, using abiraterone (ABT) as a reference...Collectively, these findings position MON as a promising lead scaffold for further optimization and experimental validation in prostate cancer therapy. The online version contains supplementary material available at 10.1007/s40203-026-00626-3.

By analyzing plasma DNA from individuals harboring germline TP53 mutations, patients receiving radiotherapy, and liver transplantation recipients, we demonstrate that ctDNA shortening can be distinguished from phagocytosis-associated cfDNA shortening through differences in the amplitude and scale parameters of intra- and inter-nucleosomal components. Moreover, leveraging tumor-related fragmentomic alterations, characterized by increased fragmentation entropy identified through cfDNA size deconvolution, significantly enhances cancer detection.

P1/2, N=102, Active, not recruiting, University of Michigan Rogel Cancer Center | Trial completion date: May 2027 --> May 2029 | Trial primary completion date: Nov 2026 --> May 2027

P2, N=218, Recruiting, Astellas Pharma Global Development, Inc.

PSMA PET-derived volumetric parameters, particularly PSMA tumor volume, provide robust prognostic information in mCRPC patients treated with abiraterone or enzalutamide. When combined with early PSA kinetics, these imaging biomarkers enable improved risk stratification and may support more individualized treatment strategies. Prospective multicenter studies are warranted to validate these findings.

Within a wide concentration range from 1 pg/mL to 100 ng/mL, the modulation depths of the resonance amplitude exhibit strong linear relationships with concentration, indicating a broad dynamic sensing range...This approach improves spectral resolution and detection reliability, enabling both qualitative identification and quantitative analysis. Overall, the proposed THz sensing platform exhibits ultrasensitive and good reproducibility, providing a promising tool for brain tumor screening and monitoring.

P2, N=120, Active, not recruiting, R-Pharm International, LLC